Answers are grounded in this paper and cite their sources.
Peripheral artery disease (PAD) is a progressive atherosclerotic condition associated with high morbidity and mortality. Serum biomarkers may improve diagnostic accuracy and prognostic risk stratification beyond traditional clinical tools. To evaluate the association between serum biomarkers and diagnostic or prognostic value in peripheral artery disease, integrating evidence across inflammatory, metabolic, and vasoactive pathways. A systematic search identified observational and interventional studies assessing serum biomarkers in adults with confirmed or suspected PAD. Data were extracted into a structured matrix including study characteristics, biomarker assays, diagnostic accuracy metrics, hazard ratios, odds ratios, and correlations with the ankle–brachial index (ABI). Twenty-two studies (21 cohorts) met the inclusion criteria. Biomarkers associated with the presence or severity of PAD included soluble-urokinase plasminogen activator receptor (suPAR) (OR 2.0, 95% CI 1.6–2.5, highest vs. lowest tertile) and inflammatory ratios: the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and monocyte-to-HDL cholesterol ratio (MHR), with regression coefficients for the ABI of β = 0.587, −1.107 and −2.993, respectively. High-sensitivity C-reactive protein (hsCRP) was also associated with the presence of PAD in some studies. Biomarkers associated in individual cohorts with amputation, mortality or chronic limb-threatening ischemia (CLTI) included NLR (OR 1.28 per unit for 30-day death or amputation in acute limb ischaemia; HR 1.14 for amputation in CLTI), growth-differentiation factor 15 (GDF-15) (adjusted HR 1.57–1.70 per ln-unit), suPAR (HR 3.1–3.5), triglyceride–glucose (TyG) index (OR 5.80 for CLTI and OR 3.92 for lower-extremity arterial disease in diabetic patients, both cross-sectional), calprotectin (HR 2.5), and lower high-density lipoprotein cholesterol (low HDL-c; HR 0.38 for MACE, normal vs. low HDL-c). Novel markers such as lipocalin-2 and urinary vanin-1 were associated with outcomes in single studies. Most studies were at moderate-to-high risk of bias, and none of the biomarkers were externally validated. Several serum biomarkers, most notably inflammatory indices (NLR, hsCRP, suPAR), GDF-15, the TyG index and HDL-c, are associated with the presence of PAD and with adverse outcomes. However, the evidence comes mainly from observational cohorts at moderate-to-high risk of bias, without external validation or demonstrated incremental value over the ABI. These biomarkers are candidates for future risk stratification rather than tools for routine clinical use.
No takes yet. Share an insight, caveat, or question.
Bichescu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: